Phase I Trial of Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Everolimus (Primary) ; Cisplatin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 29 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 14 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.